IT1256575B - Procedimento per la preparazione di immunogeni costituiti da antigeni esogeni capaci di generare non solo la risposta immune dei linfociti t helper,ma anche una efficace risposta dei linfociti t citotossici; e immunogeni cosi' ottenibili. - Google Patents

Procedimento per la preparazione di immunogeni costituiti da antigeni esogeni capaci di generare non solo la risposta immune dei linfociti t helper,ma anche una efficace risposta dei linfociti t citotossici; e immunogeni cosi' ottenibili.

Info

Publication number
IT1256575B
IT1256575B ITRM920877A ITRM920877A IT1256575B IT 1256575 B IT1256575 B IT 1256575B IT RM920877 A ITRM920877 A IT RM920877A IT RM920877 A ITRM920877 A IT RM920877A IT 1256575 B IT1256575 B IT 1256575B
Authority
IT
Italy
Prior art keywords
lymphocytes
immunogens
cytotoxic
obtainable
generating
Prior art date
Application number
ITRM920877A
Other languages
English (en)
Inventor
Francesco Balsano
Vincenzo Barnaba
Original Assignee
Cesalpino Andrea Fond
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Cesalpino Andrea Fond filed Critical Cesalpino Andrea Fond
Priority to ITRM920877A priority Critical patent/IT1256575B/it
Publication of ITRM920877A0 publication Critical patent/ITRM920877A0/it
Priority to EP93830085A priority patent/EP0601979A2/en
Publication of ITRM920877A1 publication Critical patent/ITRM920877A1/it
Application granted granted Critical
Publication of IT1256575B publication Critical patent/IT1256575B/it

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A61K47/646—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent the entire peptide or protein drug conjugate elicits an immune response, e.g. conjugate vaccines
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/44—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from protozoa
    • C07K14/445—Plasmodium
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/44—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from protozoa
    • C07K14/45—Toxoplasma
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2730/00—Reverse transcribing DNA viruses
    • C12N2730/00011—Details
    • C12N2730/10011—Hepadnaviridae
    • C12N2730/10111—Orthohepadnavirus, e.g. hepatitis B virus
    • C12N2730/10122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Biophysics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biochemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Virology (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Immunology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

Il procedimento per la preparazione di immunogeni, secondo l'invenzione è caratterizzato dal fatto di legare sinteticamente almeno un antigene esogeno alla forma esogena dell'antigene dell'envelope del virus dell'epatite B. Questi. immunogeni sono capaci di generare, nei confronti dell'antigene sinteticamente legato, non solo la risposta immune dei linfociti T helper (classe II-ristretti), ma anche una efficace risposta dei linfociti T citotossici (classe I-ristretti). Gli antigeni sinteticamente legati possono essere ad esempio scelti, dal gruppo comprendente proteine del virus dell'AIDS, proteine ricombinanti del virus dell'AIDS, peptidi sintetici del virus dell'AIDS, proteine del plasmodium della malaria e proteine del toxoplasma.L'invenzione si estende anche agli immunogeni per sé, caratterizzati dal fatto di essere ottenibili con il suddetto procedimento.
ITRM920877A 1992-12-10 1992-12-10 Procedimento per la preparazione di immunogeni costituiti da antigeni esogeni capaci di generare non solo la risposta immune dei linfociti t helper,ma anche una efficace risposta dei linfociti t citotossici; e immunogeni cosi' ottenibili. IT1256575B (it)

Priority Applications (2)

Application Number Priority Date Filing Date Title
ITRM920877A IT1256575B (it) 1992-12-10 1992-12-10 Procedimento per la preparazione di immunogeni costituiti da antigeni esogeni capaci di generare non solo la risposta immune dei linfociti t helper,ma anche una efficace risposta dei linfociti t citotossici; e immunogeni cosi' ottenibili.
EP93830085A EP0601979A2 (en) 1992-12-10 1993-03-03 Exogenous antigens bound to hepatitis B virus envelope antigen

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
ITRM920877A IT1256575B (it) 1992-12-10 1992-12-10 Procedimento per la preparazione di immunogeni costituiti da antigeni esogeni capaci di generare non solo la risposta immune dei linfociti t helper,ma anche una efficace risposta dei linfociti t citotossici; e immunogeni cosi' ottenibili.

Publications (3)

Publication Number Publication Date
ITRM920877A0 ITRM920877A0 (it) 1992-12-10
ITRM920877A1 ITRM920877A1 (it) 1994-06-10
IT1256575B true IT1256575B (it) 1995-12-11

Family

ID=11401315

Family Applications (1)

Application Number Title Priority Date Filing Date
ITRM920877A IT1256575B (it) 1992-12-10 1992-12-10 Procedimento per la preparazione di immunogeni costituiti da antigeni esogeni capaci di generare non solo la risposta immune dei linfociti t helper,ma anche una efficace risposta dei linfociti t citotossici; e immunogeni cosi' ottenibili.

Country Status (2)

Country Link
EP (1) EP0601979A2 (it)
IT (1) IT1256575B (it)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH08512200A (ja) * 1993-04-30 1996-12-24 スミスクライン・ビーチャム・バイオロジカルス（ソシエテ・アノニム） クローニング、発現およびトキソプラズマ・ゴンヂのペプチド抗原に対応するワクチン組成物
US5780448A (en) * 1995-11-07 1998-07-14 Ottawa Civic Hospital Loeb Research DNA-based vaccination of fish
ATE331030T1 (de) * 1996-11-04 2006-07-15 Ottawa Health Research Inst Verfahren zur expression von polypeptide in fishen durch wässerung in dns enthaltende lösung

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2635532B1 (fr) * 1988-07-29 1992-05-22 Pasteur Institut Particules hbsag recombinantes hybrides : caracteristiques morphologiques de l'antigene hbsag contenant 1 sequence immunogene induisant des anticorps neutralisants diriges contre hiv ou susceptible d'etre reconnue par de tels anticorps; sequences nucleotidiques codant pour de telles particules; vaccins les contenant
IT1238343B (it) * 1989-10-16 1993-07-13 Cesalpino Andrea Fond Procedimento per la preparazione di vaccini capaci di generare non solo la risposta immune dei linfociti t helper,ma anche un'efficace risposta di linfociti t citotossici,e vaccini con queste caratteristiche
WO1992011291A1 (en) * 1990-12-20 1992-07-09 Smithkline Beecham Biologicals (S.A.) Vaccines based on hepatitis b surface antigen
EP0565794A1 (en) * 1992-04-14 1993-10-20 British Biotech Pharmaceuticals Limited Induction of CTL responses

Also Published As

Publication number Publication date
EP0601979A2 (en) 1994-06-15
ITRM920877A1 (it) 1994-06-10
EP0601979A3 (it) 1994-08-03
ITRM920877A0 (it) 1992-12-10

Similar Documents

Publication Publication Date Title
Birkett et al. A modified hepatitis B virus core particle containing multiple epitopes of the Plasmodium falciparum circumsporozoite protein provides a highly immunogenic malaria vaccine in preclinical analyses in rodent and primate hosts
Heermann et al. Immunogenicity of the gene S and Pre-S domains in hepatitis B virions and HBsAg filaments
CA2331846A1 (en) Expression vectors for stimulating an immune response and methods of using the same
EP0608261A4 (en) COMPOSITION OF AN IMMUNREACTIVE HEPATITIS C VIRUS POLYPEPTIDE.
HUT50876A (en) Process for producing hepatitis b virus surface antigenes and hybrid antigenes containing same, as well as pharmaceutical compositions comprising same
JP2002520000A5 (it)
CA2102918A1 (en) Genetic vaccine for immunodeficiency viruses
Ulrich et al. New chimaeric hepatitis B virus core particles carrying hantavirus (serotype Puumala) epitopes: immunogenicity and protection against virus challenge
JPH0327400A (ja) Ｂ型肝炎ウイルスコア抗原粒子
GB8421282D0 (en) Multispecific antigenic proteins
KR860004146A (ko) 경구용 백신의 제조방법
Mimms et al. Discrimination of hepatitis B virus (HBV) subtypes using monoclonal antibodies to the PreS1 and PreS2 domains of the viral envelope
Koletzki et al. HBV core particles allow the insertion and surface exposure of the entire potentially protective region of Puumala hantavirus nucleocapsid protein
Gedvilaite et al. Segments of puumala hantavirus nucleocapsid protein inserted into chimeric polyomavirus-derived virus-like particles induce a strong immune response in mice
IT8948458A1 (it) Procedimento per la preparazione di vaccini capaci di generare non solo la risposta immune dei linfociti t helper, ma anche un'efficace risposta di linfociti t citotossici, e vaccini con queste caratteristiche
Peterson The structure of hepatitis B surface antigen and its antigenic sites
AU3422797A (en) Composition useful in preparing recombinant adenovirus vaccines
Michel et al. T-and B-lymphocyte responses to human immunodeficiency virus (HIV) type 1 in macaques immunized with hybrid HIV/hepatitis B surface antigen particles
IT1256575B (it) Procedimento per la preparazione di immunogeni costituiti da antigeni esogeni capaci di generare non solo la risposta immune dei linfociti t helper,ma anche una efficace risposta dei linfociti t citotossici; e immunogeni cosi' ottenibili.
KR920002629A (ko) B형 간염 코어 항원의 아미노산 잔기 서열
GB9810756D0 (en) Mimotopes of hypervariable region 1 of the e2 glycoprotein of hcv and uses thereof
KR950005326A (ko) 재조합 아데노바이러스 백신
Welsh et al. Quantitation of β2‐Microglobulin and HLA on the Surface of Human Cells: II. In Vitro Cell Lines and Their Hybrids
Schödel et al. Avirulent Salmonella expressing hybrid hepatitis B virus core/pre-S genes for oral vaccination
Ferrari et al. Autopresentation of hepatitis B virus envelope antigens by T cells

Legal Events

Date Code Title Description
0001 Granted